جستجوی مقالات مرتبط با کلیدواژه « تاری دید » در نشریات گروه « پزشکی »

During the COVID-19 pandemic, the presence of ocular symptoms was common in COVID-19 patients, which can cause secondary complications in the treatment of ocular diseases. On the other hand, obesity can cause secondary symptoms in infectious diseases by impairing the function of the immune system, which indicates the relationship between involvement of different tissues and dysfunction of the cellular immune system. The aim of this study was to investigate the relationship between body indexes (i.e., age, height, weight, and BMI) and the presence of ocular symptoms in patients with COVID-19.

In this cross-sectional study (from March 2021 to May 2021), ocular symptoms (including blurred vision, epiphora, photophobia, discharge and exudate, redness, pain, and itching of the eyes) and body indexes (age, height, weight and BMI) were evaluated in 108 patients with COVID-19, who were referred to Ayatollah Rouhani hospital, Babol, Iran. The independent t-test and Kruskal-Wallis statistical tests were used to examine the data relationship in SPSS software.

The results showed that the mean body weight in COVID-19 patients with blurred vision was significantly higher than COVID-19 patients without blurred vision (P=0.003, t=-3.056). The mean height of COVID-19 patients with epiphora was significantly lower than the mean height of COVID-19 patients without epiphora (P=0.018, t=2.398). Also, the BMI of COVID-19 patients with epiphora was 30.00 ±4.07 kg/m2, while the BMI of COVID-19 patients without epiphora was 27.68±4.42 kg/m2 (P=0.047, t=0.026). In COVID-19 patients with at least one ocular symptom, height was significantly lower than heigh of COVID-19 patients without any ocular symptoms (P=0.001, t=3.397).

Our results indicate the essential role of obesity in the occurrence of eye symptoms in COVID-19 patients. In this study, it was found that blurred vision, epiphora and the presence of at least one eye symptom in COVID-19 patients were significantly associated with the upward trend of BMI (as an index of obesity).

Posterior reversible encephalopathy syndrome (PRES) is a cliniconeurological syndrome presents with various clinical symptoms, like headache, alteration of consciousness, seizures, visual disturbances.Imaging predominantly shows parieto-occipital white matter changes, with vasogenic edema known as the most accepted pathophysiology.

 We report a 22-year-old primigravida who presented in near term pregnancy with seizures. Fallowed by blurred vision. Brain MRI was suggestive of PRES. Carrying out supportive treatment results in Clinical improvement with complete resolution of visual disturbances.

It is important to initiate diagnosis process and prompt treatment in order to  prevent short- and long-term neurological deficits in PRES .

Sjögren’s syndrome is the second most common systemic autoimmune disease after rheumatoid arthritis, RA, with a prevalence of about 0.5% in the general population. It occurs primarily in perimenopausal women (at a ratio of women to men of 9: 1) Sjögren’s syndrome is characterized by lymphocytic infiltration to exocrine glands. The specific autoantibodies of this syndrome are against Ro (SSA) and La (SSB). B cell dysfunction occurs in patients with Sjögren's syndrome. B lymphocyte cells produce monoclonal immunoglobulin heavy and light chains addition to producing Ro (SSA) and La (SSB). Up to 25% of patients in this situation are associated with antibody production. This study aimed to evaluate the prevalence of monoclonal immunoglobulin in patients with primary Sjögren's syndrome.

31 patients with primary Sjogren's syndrome diagnosed according to the American College of Rheumatology (ACR) criteria referred to Rheumatology Clinics of Firoozgar Hospital, Tehran, during first six months of 2016, were studied. Clinical examinations and tests carried out. We analyzed serum monoclonal immunoglobulins by immunofixation electrophoresis (IFE) on agarose gels with specific antisera to IgG, IgM, IgA, and κ and λ chains. The IFE was performed with a Helena immunofixation agarose kit (Helena Laboratories, Beaumont, TX, USA) following the manufacturer's recommended procedure. The measures of Anti-Ro, anti-La, rheumatoid factor (RF), antinuclear antibodies (ANA) with immunofluorescent method, complete blood count (CBC) with differential by peripheral blood smear, an erythrocyte sedimentation rate with western green tube, dip stick urine analysis, urine specific gravity (SG) with Refractometer (Mesu Lab Instruments Co., Guangzhou, China), turbidimetry serum complement, and the complement CH50 with ELISA were done.

Most of (87%) patients were female. The mean age of patients was 45.32±12.02 years. The majority of the patients (94%, 29 cases), ocular sign was observed. Xerostomia were common in 84% cases (n=26). Arthralgia/arthritis and submandibular enlargement were common 48% and 19% of patients, respectively. Lymphadenopathy, lung involvement and parathyroid, each was prevalent in 16% of patients. Vasculitis in 13% and Raynaud's phenomenon in 6% of the patients were common. Liver and kidney involvements with the lowest prevalence, each was prevalent in 3% (1 person) patients. RF and the erythrocyte sedimentation rate (ESR) were abnormal in 22.58% and 12.90% of patients, respectively. The immunofluorescent antinuclear antibody (ANA or FANA) pattern, C3 and C4 complements levels were abnormal in 16.12%, 12.90% and 6.4% of patients, respectively. In 29% (n=9), monoclonal antibodies were higher than normal. IgG, IgM and IgG, were abnormal in 19.3% (n=6), 6.4% (n=2) and 3.3% (n=1), respectively.

Monoclonal immunoglobulin levels in patients with primary Sjogren's syndrome increases. To achieve more definitive and reliable results, this study should be repeated with larger sample size and at different times.